PCRX
Pacira BioSciences, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Pacira BioSciences (PCRX) Stock: Buy, Sell, or Hold?
$36.46
-0.03 (-0.08%)
âŧ
5d:
+0.16%
30d:
+0.41%
90d:
+57.29%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (43%)
Quality Score
46/100
Position
FAIR
30-Day Fair Range
$30.80 â $38.73
Position: FAIR
Forward P/E & Valuation
10.5x
STRETCHED
vs 7.2x historical avg
Wall Street Target
$33.57
-7.9% vs target
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$36.37 / $36.50
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: PCRX is fairly priced but lacks strong directional signals. At 13.6% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Get Alerted When PCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$43.05
Based on 11.7% avg growth
INTRINSIC VALUE TODAY
$26.73
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PCRX is currently trading at $36.46, which is considered fair relative to its 30-day fair value range of $30.80 to $38.73. From a valuation perspective, the stock is trading at a premium (Forward PE: 10.5) compared to its historical average (7.2). At these levels, the market is pricing in 13.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PCRX is in a strong uptrend. The price is currently testing key support at $36.37. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PCRX scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PCRX is in a strong uptrend. The price is currently testing key support at $36.37. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PCRX scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$30.80 -
$38.73
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.9%
Trading Range & Key Levels
30-Day Trading Range
$30.80 -
$38.73
Current vs Trading Range
FAIR
Support Level
$36.37
Resistance Level
$36.50
Current Trend
Strong Uptrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BEARISH: Trading above Wall St target ($33.57)
- NEUTRAL: PE elevated vs history but 13.6% growth expectation is conservative given 483% recent growth
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
10.54
Wall Street Target
$33.57
(-7.9%)
Revenue Growth (YoY)
-1.6%
Earnings Growth (YoY)
483.3%
Profit Margin
5.1%
Valuation Premium vs History
+13.6% premium
PE vs Historical
10.5 vs 7.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+13.6%
(market-implied from PE analysis)
1-Year Target
$41.42
(+14%)
2-Year Target
$47.05
(+29%)
3-Year Target
$53.45
(+47%)
3-Yr Target (if PE normalizes)
(PE: 11â7)
PE COMPRESSION
$36.51
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 19.4%)
$117.04
(+221%)
Base:
(SPY PE: 10.5, Growth: 19.4%)
$62.12
(+70%)
Bear:
(PE: 7.2, Growth: 19.4%)
$42.43
(+16%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (39x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 39.24 | Current EPS (TTM): $0.93
Bull Case
$80.28
(+120%)
Analyst growth 100.0%, PE expands to 43.2
Base Case
$72.98
(+100%)
Market implied 100.0%, PE stable at 39.2
Bear Case
$24.81
(-32%)
Severe decline -20.0%, PE contracts to 33.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share PCRX Analysis
Share this live PCRX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (PCRX)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Jul 20, 2026
Daily AI digest
AI Retail Discussion Summary:
One bullish StockTwits message expresses optimism about $PCRX, with no recent news articles available.
Key Retail Themes:
Positive sentiment towards $PCRX
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 7:16 AM ET
Data refreshes hourly during market hours. Next update: 8:16 AM
Data refreshes hourly during market hours. Next update: 8:16 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 33 SELL |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$687 | 52 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 53 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive PCRX Research Pages
